Vedanta Biosciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2010-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.vedantabio.com
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
- Conditions
- Clostridioides Difficile Infection RecurrenceDiarrhea InfectiousClostridium DifficileClostridium Difficile Infection RecurrenceC.Difficile DiarrheaClostridioides Difficile InfectionClostridium Difficile InfectionsC. Diff InfectionRecurrent Clostridium Difficile InfectionCDI
- Interventions
- Biological: PlaceboBiological: VE303
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Vedanta Biosciences, Inc.
- Target Recruit Count
- 852
- Registration Number
- NCT06237452
- Locations
- 🇧🇬
UMHAT Burgas AD, Burgas, Bulgaria
🇧🇬MBAL Dr. Ivan Seliminski - Sliven AD, Sliven, Bulgaria
🇮🇹AOU Pisana - Stabilimento di Cisanello, Pisa, Italy
VE202 in Patients with Mild-to-Moderate Ulcerative Colitis
- Conditions
- Ulcerative ColitisColitis, Ulcerative
- Interventions
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Vedanta Biosciences, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05370885
- Locations
- 🇺🇸
Clinical Applications Laboratories, San Diego, California, United States
🇺🇸Digestive Health Specialists, Dothan, Alabama, United States
🇺🇸GastroIntestinal BioSciences, Los Angeles, California, United States
First-in-human Study of VE303 in Healthy Adult Volunteers
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Vedanta Biosciences, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04236778
- Locations
- 🇺🇸
Pharmaron CPC, Baltimore, Maryland, United States
Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
- Conditions
- Metastatic CancerMelanomaGastric CancerGastroesophageal Junction AdenocarcinomaColorectal Cancer
- Interventions
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Vedanta Biosciences, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT04208958
- Locations
- 🇺🇸
University of California Los Angeles, Santa Monica, California, United States
🇺🇸Baylor Scott and White Center for Advanced Heart and Lung Disese, Dallas, Texas, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
- Conditions
- Clostridium Difficile Infection RecurrenceClostridioides Difficile Infection RecurrenceClostridioides Difficile InfectionClostridium Difficile InfectionClostridioides DifficileCDIClostridium Difficile
- Interventions
- Drug: PlaceboDrug: VE303
- First Posted Date
- 2018-12-27
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Vedanta Biosciences, Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT03788434
- Locations
- 🇺🇸
Innovative Research of West Florida, Clearwater, Florida, United States
🇺🇸Gastro Florida, Clearwater, Florida, United States
🇨🇦Moncton Hospital, Moncton, New Brunswick, Canada